NewAmsterdam Pharma B.V.
- Address
- Gooimeer 2/35
Sponsor Overview
Specializations
Cardiovascular disease
NewAmsterdam Pharma B.V. focuses on clinical research in atherosclerotic cardiovascular disease, with attention to coronary artery plaque burden, arterial narrowing, and broader cardiovascular risk in adults receiving lipid-lowering treatment.
- Atherosclerotic cardiovascular disease
- Coronary atherosclerosis
- Non-calcified plaque
The sponsor’s studies include outcomes related to coronary plaque characteristics and the progression of atherosclerotic heart and blood vessel disease.
Lipid management
Its research activity is centered on LDL cholesterol reduction in participants whose current lipid-modifying therapy is not sufficiently effective, including people with persistent elevated LDL-C.
- LDL-C lowering
- Lipid-modifying therapy
- Combination lipid therapy
Clinical interest extends to fixed-dose combination approaches and monotherapy strategies aimed at improving lipid control.
Metabolic disease
The sponsor also studies adults with type 2 diabetes and metabolic syndrome, reflecting an interest in cardiometabolic conditions linked to dyslipidemia and vascular disease.
- Type 2 diabetes
- Metabolic syndrome
- Cardiometabolic risk
These programs address patients whose metabolic disorders coexist with elevated cardiovascular risk and abnormal lipid profiles.
Cardiovascular outcomes
Research interests include prevention of major adverse cardiovascular events, with focus on myocardial infarction, stroke, cardiovascular death, and coronary revascularization.
- Major adverse cardiovascular events
- Myocardial infarction
- Stroke
These studies link lipid lowering with clinically meaningful cardiovascular event reduction in patients with established vascular disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy of Obicetrapib and Obicetrapib plus Ezetimibe in Reducing LDL-C in Patients with Type 2 Diabetes and/or Metabolic Syndrome |  Czechia Slovakia The Netherlands | Recruiting |
| Evaluation of Obicetrapib and Ezetimibe Fixed Dose Combination on Coronary Plaque in Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Study | Czechia Hungary Italy Poland Spain The Netherlands | Recruiting |
| Evaluation of Obicetrapib on Major Adverse Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients on Maximal Lipid-Modifying Therapy |  Bulgaria Croatia Czechia Denmark Finland Germany Hungary Italy Latvia Poland Slovakia Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 256 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases3 trials359 other sponsors
- 2.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
256 centres- Address
- Moelleparkvej 4, 9000 Aalborg
- Address
- Albinusdreef 2, 2333 ZA Leiden
- Address
- Ul. 1 Maja 323, 41-710 Ruda Śląska
- Address
- Langeweg 336, 3331 LZ Zwijndrecht
- Address
- Albert Schweitzerplaats 25, 3318 AT Dordrecht
Want to get in touch with this sponsor?
Send a question and we'll pass it on to NewAmsterdam Pharma B.V..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.